TDO2 inhibitor
By developing a new small molecule compound with an imidazoloisoindole structure, specifically inhibiting IDO1 or TDO2 enzymes, the immunosuppression and tumor resistance caused by tryptophan degradation are solved, the anti-cancer treatment effect is enhanced and treatment plans are provided for immune-related diseases.
Patent Information
- Application Number
- CN202210532542.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2016-11-21
- Filing Date
- 2016-12-23
- Publication Date
- 2025-07-25
- Estimated Expiration
- 2036-12-23
AI Technical Summary
The prior art is difficult to effectively inhibit the activity of tryptophan 2,3-dioxygenase (TDO2), resulting in the problem of immunosuppression, tumor resistance, chronic infection, HIV infection, AIDS, autoimmune diseases and immune tolerance not effectively resolved.
A new type of compounds with an imidazoloisoindole structure have been developed that can specifically inhibit IDO1 or TDO2, or simultaneously inhibit the tryptophan degradation of these two enzymes, and regulate their activity through small-molecular compounds.
It enhances the activation ability of T cells, improves the effectiveness of anti-cancer treatments, and reduces immunosuppression and tumor resistance, providing therapeutic strategies for immune-related diseases and disorders.